Sanofi (SNY) EBT (2009 - 2026)
Sanofi (SNY) posted EBT of $16.6 billion for Q2 2026, up 14.85% sequentially from $14.4 billion in Q1 2026, and up 20.47% YoY from $13.8 billion in Q2 2025.
Sanofi (SNY) EBT (2009 - 2026) Analysis & Trends
Sanofi has reported EBT for 18 years, with the latest figure at $16.6 billion in Q2 2026.
- Quarterly EBT rose 20.47% year-over-year to $16.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $88.4 billion (up 91.48% YoY) and the FY2025 annual result came in at $7.2 billion, up 47.71% from the prior year.
- EBT rose to $16.6 billion in Q2 2026 per SNY's latest filing, from $14.4 billion in the prior quarter.
- Over five years, EBT peaked at $49.2 billion in Q4 2023 and troughed at $4.9 billion in Q4 2024.
- A 5-year average of $18.1 billion and a median of $13.4 billion in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2024: EBT surged 242236.53% in 2022, then slumped 90.11% in 2024.
- Over 5 years, EBT stood at $40.4 billion in 2022, then rose by 21.65% to $49.2 billion in 2023, then plunged by 90.11% to $4.9 billion in 2024, then jumped by 162.14% to $12.8 billion in 2025, then jumped by 30.01% to $16.6 billion in 2026.
- According to Business Quant data, EBT over the past three periods registered $16.6 billion, $14.4 billion, and $12.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 6.75 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 4.28 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -683.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.27 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.80 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.77 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.25 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -653.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 474.95 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.58 Bn |
| Mar 31, 2026 | 14.44 Bn |
| Dec 31, 2025 | 12.76 Bn |
| Sep 30, 2025 | 44.60 Bn |
| Jun 30, 2025 | 13.77 Bn |
| Mar 31, 2025 | 12.59 Bn |
| Dec 31, 2024 | 4.87 Bn |
| Sep 30, 2024 | 14.94 Bn |
| Jun 30, 2024 | 10.98 Bn |
| Mar 31, 2024 | 11.72 Bn |
| Dec 31, 2023 | 49.20 Bn |
| Sep 30, 2023 | 14.61 Bn |
| Jun 30, 2023 | 12.87 Bn |
| Mar 31, 2023 | 13.01 Bn |
| Dec 31, 2022 | 40.44 Bn |
| Sep 30, 2022 | 13.90 Bn |
| Jun 30, 2022 | 12.62 Bn |
| Mar 31, 2022 | 12.49 Bn |
| Dec 31, 2021 | -16.70 Mn |
| Sep 30, 2021 | 13.43 Bn |